结直肠癌肺转移术后复发性肺转移治疗进展  

Treatment progress for recurrent pulmonary metastasis after pulmonary metastasectomy of colorectal cancer

作　　者：黄晋杰 李奕男 王彩琴 黄晓卉[3] 王荣昌 Huang Jinjie;Li Yinan;Wang Caiqin;Huang Xiaohui;Wang Rongchang(Department of Gastrointestinal Surgery,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Anesthesiology,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Laboratory of Surgery,the First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510080,China)

机构地区：[1]广州医科大学附属第一医院胃肠外科,510120 [2]广州医科大学附属第一医院麻醉科,510120 [3]中山大学附属第一医院外科实验室,广州510080

出　　处：《中华普通外科学文献(电子版)》2025年第1期50-54,共5页Chinese Archives of General Surgery(Electronic Edition)

基　　金：广东省基础与应用基础研究基金项目(2020A1515110056);广州市科技局项目(202102010172,202201020543)。

摘　　要：结直肠癌是目前全球范围内发病率和死亡率较高的恶性肿瘤之一,而肺是其常见的转移部位。对于结直肠癌肺转移患者,手术切除是目前的主要治疗手段,但术后肺转移复发的风险较高。本文综述了近些年来结直肠癌肺转移术后复发性肺转移的治疗进展,重点介绍了局部治疗(如射频消融、微波消融和立体定向放疗)以及全身治疗(包括化疗、靶向治疗和免疫治疗)的最新研究进展。未来研究应着重于优化个体化治疗策略、识别有效的生物标志物以及多学科协作,同时在减毒增效的前提下,进一步提高患者的长期生存率和改善生活质量。Colorectal cancer(CRC)is one of the most common malignancies worldwide,with high rates of incidence and mortality,and lung is a frequent site of metastasis.Surgical resection remains the primary treatment for CRC patients with pulmonary metastases,yet postoperative pulmonary recurrence is common.This review provides an overview of recent advances in managing recurrent pulmonary metastasis following pulmonary metastasectomy in CRC,with a focus on local therapies(radiofrequency ablation,microwave ablation,stereotactic body radiation therapy and so on)and systemic therapies(such as chemotherapy,targeted therapy,immunotherapy).Future researches should focus on optimizing individualized treatment strategies,identifying effective biomarkers,and enhancing multidisciplinary collaboration to improve patients’outcomes.The goal remains to boost long-term survival rates and quality of life while reducing treatment-related toxicity.

关 键 词：结直肠外科手术 肿瘤转移 复发性肺转移 局部治疗 全身治疗 

分 类 号：R735.34[医药卫生—肿瘤]